In the third quarter 2024, Arcus recognized $41 million in license and development services revenue related to the advancement of programs and Taiho's exercise of its option for the license of ...

HAYWARD, Calif., February 18, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

HAYWARD, Calif., January 21, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

(RTTNews) - Arcus Biosciences, Inc. (RCUS), a clinical-stage, biopharmaceutical company, announced Tuesday that Taiho Pharmaceutical Co., Ltd. exercised its option for anti-TIGIT antibodies ...